June 2, 2010 (Kansas City, Missouri) — A treatment strategy that involves the use of a vascular closure device and bivalirudin (Angiomax, the Medicines Company) reduces the risk of periprocedural ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback